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Inflammatory bowel diseases (IBD) are prevalent diseases affecting the 
gastrointestinal system of human beings. The disease affects over 1 million people 
per year in the United States alone. However, the cause of the disease is still highly 
debated. There are two predominant diseases of IBD called Crohn’s Disease and 
Ulcerative Colitis. The objective of the study was to evaluate the therapeutic effect 
of two methodologies of treatment using a novel formulation of a compound named 
RDP-58 and Cold Plasma (CP) technology in Dextran Sulphate Sodium (DSS) 
induced colitis model in mice. Cold plasma is a partly ionized gas, which is 
generated by a high-voltage electric field at a low pressure. CP technology has found 
its use in medical sterilization, wound healing, skin diseases and tissue regeneration. 
CP can be used with a biological interface as it has bactericidal effect, induces 
apoptosis, enhances coagulation and increases cell proliferation. The effect of CP as 
a stand-alone and in combination with 5-Amino Salycylic Acid (5-ASA) in the 
mouse colon in normal and disease conditions was evaluated. The disease activity 
(DAI) [Index using Body Weight, Stool Consistency, Blood in Stool as visible or 
occult] was measured everyday to evaluate the progress of the disease. Colon tissue 
was collected to estimate Tissue and DNA damage. The study brings state of the art 
plasma technology onto a biological platform for in vivo application in living 
animals. The study for the first time demonstrates in vivo application of Cold Plasma 
in a live animal. 
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“The best way to predict the future is to invent it.” 
-­ALAN  KAY  
(ARCHITECT  AND  CONCEIVER  OF  THE  LAPTOP  COMPUTER)  
  
I would like to start the thesis by paraphrasing one of the greatest visionaries of our time 
Alan Kay. He is one of the inventors of the Smalltalk programming language and one of the 
fathers of the idea of Object Oriented Programming. The quote epitomizes the spirit and the 
vision of the project, and also of the plasma prototype which was used. 
The origins of most of the very successful inventions in history have always been humble 
and ordinary. However, the ideas and dreams envisioned by their scientists are anything but 
ordinary. The goal of the project was to bring together advanced plasma science technology 
and medical engineering onto an animal model platform to seamlessly create integrated 
solution for ulcerative colitis patients. This revolutionary product transcends the limitations 
and problems associated with the usage of conventional drug and diet regime.  
The prime aspiration is to make the laboratory an abode of discovery and excellence, which 
cultivates a culture of innovation. The idea to create a product which uses the plasma 
technology inside the colon of a live animal may seem like a moon shot, but this could set a 
precedent in the nascent plasma-based biomedical industry. Many conformist therapies 
available today targeting the disease spread themselves thin to make a plethora of products 
to defuse risk, hence they end up making products, which are evolutionary, but are not 
revolutionary.  
All the energy and resources of the Drexel Plasma Laboratory and the Gastroenterology 
Laboratory were invested on one novel method of treating ulcerative colitis; however, using 
a functional technology that is robust adaptable and designed for  minimally invasive 
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procedure in animals and humans. The onus is not on creating a niche, ghettoized product 
which only caters to one specific disease; but to take it many steps further into the emerging 
biomedical product industry as a pivotal solution. The following report is a preview of the 
things to come in the future, so let us not only dream of the future, but actually engineer it. 
1. INTRODUCTION 
1.1 COLD ATMOSPHERIC PLASMA 
Plasma is the current engine revolutionizing the way we look at the world. This science 
seamlessly integrates multiple disciplines of advanced physics, chemistry and material science 
and brings all of these onto humongous application platforms of medicine and biology. The huge 
televisions we see everyday use the same technology. The platform of plasma science is changing 
the way we function, think and apply technology. This is the state of the art in projection of 
moving images today. Plasma has a plethora of applications ranging from solving complex 
problems of national defense to treating contaminated water. Applications pertaining to medicine 
have come on to the forefront in view of recent breakthroughs, namely atmospheric plasma which 
is non-thermal. The most powerful and evident form of a plasma discharge is “lightening”; this is 
a form of thermal plasma which in most cases can be fatal. Electrons heat up relatively faster as 
compared to their environment. Hence a non-thermal plasma application was devised for 
applications which pertain to contact with the living world. Energy transfer from the electrons can 
be engineered in lieu with cooling of uncharged molecules; as a result gas remains at a low 
temperature41, 42. The discharge of electricity in a gaseous environment produces this unique state 
of matter called plasma. This property of material bending gives us a different mode of activating 
certain species of gases which can be harnessed to treat specific surfaces; this has given us a 
striking opportunity to understand dynamics of surface interactions of plasma with non-biological 
materials namely metal surfaces, fabrics and image projections. Plasma with minute ionization 
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can be engineered to non-thermally converse with surfaces which are sensitive like living tissues 
and cells43.  
Recent technological breakthroughs at Drexel Plasma Institute and Eindhoven University of 
Technology in Netherlands have introduced a revolutionary concept of applying cold plasma 
treatment to medical science. A simple plasma needle device which generates a low-intensity 
atmospheric discharge by excitation of a mixture of helium and air was invented by the 
researchers at this university44, 45. The complications which arise due to the Western medicine’s 
ghettoized view of the human body are often complex and lead to increased side effects. This 
combined with increased research and development costs and resistance of microbes due to 
constant interaction with these formulations pave the way for a foray of alternate medical 
solutions. Chinese medicine and ancient Eastern medicine treats the whole human body as a 
system, hence treats a disease holistically by empowering the human body to fight back. Parallels 
can be drawn between the application of plasma and other Eastern medication which gently 
nudges the immune system to fight back and does not indulge in carpet bombing. Plasma therapy 
may enhance the body’s healing and renewal capabilities by providing a support and by not 
causing a serious tissue or system damage compared to conventional treatment. The rationale 
behind using plasma for curative purposes stems from the fact that plasma treatment is not based 
on inflicting a physical or mechanical or thermal injury, but by giving out a chemical stimulation 
to the body cells. This is done by a species of highly reactive radicals, which have a short 
lifespan; and have a targeted approach on an area of tissue and do not leave an imprint. Radicals 
are present in huge numbers in an organism and they play a significant role in activating and 
sustaining various physiological processes, example nitric oxide produced regulates blood vessel 
function while active oxygen species are produced by inflammatory sites to counter infection46.It 
has been the most pivotal pursuit of modern science to understand the complex functioning of 
nature. The way nature programs, plans and executes most of the mundane and esoteric activities 
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is shrouded in mystery. Cold plasma appears that it can by the generation of nitric oxide and 
reactive oxygen species can actually mimic nature. This is a potentially encouraging observation 
because cold plasma creates just the right amount of these radicals and delivers them specifically 
without causing extensive oxidative stress, but in required amounts to trigger the chain reaction of 
cell response47. The most prevalent and persistent question that researchers face when dealing 
with subjecting tissue samples to varied forms of energy like mechanical, thermal or nuclear is 
the problem of necrosis or accidental cell death. A fatal injury which is subject on to a cell leads 
to membrane architecture damage or the leakage of cellular fluids is a direct consequence of 
necrosis. This results in a counter reaction by the immune system and results in an inflammation 
at the source of injury. This is a common fatality in conventional forms of surgery as well as 
specialized treatments like cryogenic, laser based surgeries however, plasma offers a better 
solution as it treats the tissue surface without accidental cell death, tissue scarring or 
inflammation at the site of application. Several parameters decide the level of plasma action on a 
living tissue; these are exposure time, power and the composition of plasma based on its gaseous 
environment. The primary reasons why extensive research was conducted in this study were 
rooted in solid study rationale. In vivo application of plasma inside a living animal was studied 
for the first time during the course of this study. The basis for using the alternate form of 
treatment was deeply rooted in the foundation of targeted treatment which can be administered 
using plasma; they are as follows: 
1.1.1 BACTERICIDAL EFFECT 
Plasma can be effectively used to make the bacteria, bacteriostatic or can be used to kill 
bacteria48. This is due to the plasma’s selective significance to eukaryotic cells as it can remove 
microbial infection without physically damaging the Meta Structure and architecture of the 
tissue. Key advantage being the induction of bacterial damage due to the reactive oxygen species 
induced mechanism. This works exactly the way body’s natural defense mechanism does. 
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1.1.2 CELL DETACHMENT 
Cell migration is one of the applications of plasma treatment as this causes a temporary 
detachment of cell adhesives (extracellular matrix). Cells which are dislodged reattach after a few 
hours. This is an added advantage as this phenomenon is limited only to a primary layer of the 
exposed cell; this might be probably due to the electrostatic membrane interaction which is 
facilitated by the plasma electron charge.  
1.1.3 CELL ACTIVATION 
Cells show a definitive increase in the intervals in which they proliferate, adhere and move which 
mostly explains the great value, this adds to tissue repair.  
1.1.4 APOPTOSIS 
Programmed cell death is the most critical and important functions of the host body as this 
regulates the death and replenishment of cells. Plasma treatment is effective in inducing apoptosis 
in a wide range of cells including endothelium, epithelium, smooth muscle and fibroblasts. This is 
a unique way of reaching nature’s modus operandi of disposing off old and dead cells without the 
side effects of inflammation 45, 49. 
The above benefits and advanced treatment facets of plasma was the scientific rationale behind 
the usage of plasma to treat colitis in the Dextran Sulphate Sodium (DSS) model of mice. The 
most striking feature of cold plasma is disinfection and removal of tissue without inflammation. 
The surfeit of applications lead to plasma usage in wound care, skin surface sterilization, in vivo 
disinfection even in the most sensitive of sites say the eye, urinary, digestive organs. Future 
breakthroughs might mushroom in treatment of diseases in patients who are 
immunocompromised45. 
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1.2 INFLAMMATION 
Inflammation is a complex reaction or a response of the host as a counter mechanism towards an 
external agent or due to physical injury1, 2. The immune system of the host tries to reduce the 
damage and limits the extent, by killing the infecting agent and by helping the body heal and 
recover the effected tissue or organ2, 3. The mechanism involved in the afore mentioned 
phenomenon, is often very well conceived and coordinated by the immune system. This involves 
a regulation of signals that initiate, sustain and suppress inflammation, the signals are a part of a 
two-pronged positive and negative feedback loops and these are curtailed with a tight leash by the 
host’s immune system. However, even a slight disparity in these signals creates a sizable 
disturbance in the inflammatory response and the healing process, which results in an abnormal 
immune response leading to extensive damage to the tissue and organs2, 4. Inflammation comes in 
two forms; an “acute inflammation” which can sometimes morph into the complex “chronic 
inflammation”3, 4. Acute inflammation most of the time presents itself as an instant strike 
response of the defense system as a counter reaction to an injury or infection and is characterized 
by the activation of leukocytes in the site of injury. Neutrophils are the initial foot soldiers which 
flood and accumulate in the area of inflammation4, 5. In extreme cases, when neutrophils by 
themselves are not capable of controlling and curbing the spread of the disease, they are replaced 
by the sophisticated and advanced lymphocytes, macrophages and monocytes. This is mostly in 
the case of chronic inflammation, which is an advanced stage of the disease 3, 4. The whole gamut 
of inflammatory reactions is controlled by cytokines, lipid mediators like prostaglandins, 
leukotrienes and by platelet activating factors. As an inflammation response, these intermediaries 
mediate and play a pivotal role in the activation and recruitment of leukocytes. The inflammation 
most of the time results in vasodilation and increased membrane permeability of blood vessels1, 3, 
4. Neutrophils also referred to as polymorphonuclear leukocytes are richly endowed in the blood; 
these are the agents of the first line of defense. They consist of primary and secondary 
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Cytoplasmic granules which are required for breaking up of toxic substrates and are critical in 
microbicidal activities. Phagocytosis is the mechanism through which neutrophils, monocytes, 
macrophages and mast cells ingest and destroy bacteria and other infectious or chemical or 
biological agents. When the inflammatory response is activated, it initiates a complex series of 
chemical reactions leading to the release of an array of soluble inflammatory mediators like 
leukotrienes, chemokines, cytokines and chemical cascades. They mediate and control the 
neutrophils and channel them into the endothelial cells from the blood circulation with the help of 
adhesion of molecules 2, 4, 5.  
The immunoglobulin superfamily comes into play with its members like adhesion molecules 
(selectins and integrins) and they facilitate the interaction between the neutrophils and 
endothelium. The adhesion molecules on the outer cover of the neutrophils are activated and they 
have a high affinity to their complimentary receptors on the endothelial cells and they form a 
complex 2, 3, 6. This process is referred to as the adhesion cascade and this consists of various 
intricate physical processes like tethering, rolling, adhesion and transmigration of neutrophils2, 5-8. 
The mode of infectious agent destruction by neutrophils is through Phagocytosis. The lysosomes 
of neutrophils are combined with the plasma membrane of the micro organism to form an 
intermediary complex known as phagolysome. The structure of the phagolysome owing to its 
degranulation prevents the release of toxic byproducts into the external environment; however, in 
certain cases these toxic products are released into the outer environment to a large extent that the 
defense mechanism is overwhelmed and this result in eventual tissue damage5, 6, 9. The 
neutrophils are extremely important in controlling the disease prevalence; however, in extreme 
cases they go haywire and create extensive harm to the host 5, 10. Neutrophils are cells which do 
not have a long lifespan and usually disintegrate in 48 hours. As old neutrophils die, the body 
synthesizes new neutrophils and the immune system keeps flooding the effected tissues with 
these nascent agents. When neutrophils are not sufficient enough to control the infection, the 
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system activates the second line of defense as is the case in chronic inflammation. The second 
line of defense consists of intelligent squadron of monocytes, macrophages and T-lymphocytes. 
This phase is exhibited by a cascade of processes which include tissue destruction, healing and 
inflammatory cell recruitment2. This chronic inflammation is characteristic with the torrent of 
macrophages, lymphocytes and plasma cells at the site of inflammation. The macrophages are 
intricate killer cells which phagocytose the damaged tissue and microbes much more powerfully 
than neutrophils 4.  
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The following figure is a schematic of the various processes which are involved in 
inflammatory response11.  
 
 
 
 
 
 
 
 
 
1.3 INFLAMMATORY BOWEL DISORDERS 
Inflammatory bowel disorders (IBDs) are characterized by the inflammation of the intestine; two 
very prevalent forms of the disease are Crohn’s disease and Ulcerative Colitis. The onset of the 
disease is often debated and is always shrouded in mystery. There have been three postulations as 
to the occurrence of the disorder. They are:  
1. Reaction to an existent infection in the intestine 
 2. Defective barrier between mucosa and luminal antigens 
 3. Abnormal immune response system by the host’s defense mechanism.  
  
Figure  1:  Steps  of  Inflammatory  Response  at  the  site  of  injury  (Adapted  from  the  Goodpsych  Website)  
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All these cases present inflammatory cascade reactions which lead to inflammation in the 
intestine.  The disease instigates a series of steps which start with the breach of the barrier 
between the intestine and infectious agents. The damaged wall bridges the gulf and exposes the 
lamina propria immune cells to the internal bacteria and its products. Tissue injury results as the 
soluble products of activated inflammatory cells come into contact with the bacteria. Therapy to 
cure and control the disease should be designed to block the pro-inflammatory mediators at the 
end of the cascade as this would decrease the current drift of luminal bacteria and has to correct 
the immune system which has gone of the tangent12, 13.     
 
Figure 2: The artist's rendition shows the disturbance in the digestive tract due to IBD14. 
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1.4 COLON 
The colon is one of the most important portions of the digestive system, in most vertebrates 
colon is the last portion of the digestive system. In mammals the colon consists of four parts 
namely ascending colon, descending colon, transverse colon and the sigmoid colon. The 
cecum is present at the beginning of the ascending colon and is at an intersection of small 
and the large intestine. The contents of the large intestine are liquids at the time when 
chyme enters the colon; however, colon being an absorptive organ absorbs the liquid and 
change the content into a solid form as they reach the rectum. The most important functions 
of the colon are maintaining the water balance absorbing bile and certain vitamins especially 
vitamin K which is vital for clotting of blood, storing waste and reclaiming water. The 
chyme is processed and 90% of almost all the nutrients and water are absorbed by the time it 
reaches the large intestine55.  
The following figure is an artist’s rendition of the colon shown in red56 
 
 
 
 
 
 
 
 
  
Figure  3:  Graphical  representation  of  the  colon  in  red  color  
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1.5 ULCERATIVE COLITIS 
Ulcerative colitis is an inflammatory disorder effecting the mucosa and sub-mucosa of the 
colon15. Ulcerative colitis is one of the chronic inflammatory bowel diseases along with Crohn’s 
disease, Diversion Colitis, Segmental Colitis, Collagenous and Lymphocytic Colitis. This disease 
is prevalent in almost all regions of the world with highest incidence in northern climates 
specifically in North America, Great Britain and Scandinavia15. Ulcerative colitis also affects 
Jews more than non-Jews and is highly observed in whites than in blacks. The disorder shows 
more incidences towards urban communities than rural communities. It can strike varied age 
groups right from just born to just near death with maximum cases being reported in the age 
group of 20-40.Epidemiology of U.C is often mired in controversy regarding its incidence as no 
evidence suggests that a particular lifestyle, diet or food plays any significant plays an important 
part. There is some research which states that smoking surprisingly plays a role of a protective 
agent in preventing the disease and certain studies have shown that recent smoking cessation may 
increase a risk factor of disease development 18-20.  
Ever since the inception of research into this field doctors and researchers have suggested 
psychosemantic factors as important reasons in the pathogenesis of the disorder. However, as 
most of the patients presented with the disorder do not have a higher incidence of psychological 
problems; this theory has been debunked. In one specific study involving thirty four patients only 
20% of the subjects with recent onset of the disease related an emotionally disturbed episode 
from their past21. Infectious etiology of the disease also put up several usual suspects on the dart 
board. Example: Mycobacterium Paratuberculosis, Chlamydia, Cytomegalo virus and yersinia. 
However, there have been no confirmatory studies of these findings. Genetic basis has been 
suggested in the development of IBDs due to familial tendency of the disorder22, 23. Relevant 
markers of auto-immune diseases like Anti Neutrophilic Cytoplasmic Antibody (ANCA) have 
been noted for the disease. One specific pattern of ANCA Perinuclear Anti Neutrophilic 
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Cytoplasmic Antibody (pANCA) has been noted in 60-80% of cases with UC. Many animal 
models suggest inappropriate attack by the immune system to be a principal pathogenesis of the 
disease. Specific initiators of the inflammatory reaction may be any of the above, but the 
pathologic changes of the system can explain manifestations clinically. Predominant of which are 
diarrhea, rectal bleeding and abdominal pain. In severe cases anemia and hypoalbuminemia are 
also reported. Inflammation is mostly observed in the colon and in the mucosa and the sub-
mucosa. Epithelial cell degeneration is often observed in the tip of the intestinal crypt; the crypt 
abscess is the initial lesion in UC. This occurs due to the polymorphonuclear leukocytes 
accumulation within the intestinal crypt tip, the epithelial crypt cells die and chronic 
inflammatory cells including the neutrophils enter the crypt. The dismemberment of the colon 
decreases the fluid exchange on its surface leading to abnormal electrolyte absorption, hence 
creating loose stools. As a result of the inflammation, the vessels of the mucosa and sub-mucosa 
enlarge and tissue granules develop in the ulcerated part of the intestine, as part of the repair 
mechanism. The ulcerations destroy the mucosa in highly vascular sections leading to bleeding in 
the gut lumen. In the next phase, the repair mechanism continues to fill the ulcerations with 
granulated tissue, which leads to collagen being deposited in the lamina propria, which leads to 
formation of pseudopolyps as an expression of the granulated tissue causing clinical bowel 
obstruction12, 23-27.  
1.6 THERAPY FOR ULCERATIVE PROCTITIS AND COLITIS 
Sulfasalazine or Corticosteroids have been the common form of therapy for the disease for a long 
time. Immunosuppressive drugs like 6-mercaptopurine and azathioprine are currently being used 
in higher number of cases for both active and remittent forms of the disease. Sulfasalazine 
consists of a sulfapyridine linked to 5-ASA through an azo bond 28-30. The drug after being 
ingested orally; enters the system and less than 1/3 of the drug is absorbed from the jejunum, a 
portion of which is excreted through the urine un-metabolized. The remaining of the un-absorbed 
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portion remains in the small bowel as it is excreted through the bile. The drug moves through the 
intestine and interacts with the bacterial flora, which cleavethe azo bond separating Sulfasalazine, 
5-ASA and Sulfapyridine 28, 31. The sulfapyridine is metabolized by the liver after being absorbed 
from the colon and is later excreted through the urine. 5-ASA is minimally absorbed from the 
colon and remains in contact with colonic mucosa and is excreted through the feces. If any of 
these are taken as single agents without Sulfasalazine, they are absorbed in the jejunum and are 
excreted and never reach the distal bowel site. As 5-ASA is the only segment reaching the distal 
colon, it is the active moiety causing the therapy; hence a new class of drugs called 
aminosalicylates came into play32-34.  
1.7 MECHANISM OF ACTION OF 5-ASA 
Sulfasalazine with an active moiety 5-ASA, inhibits both the proliferation of T cells and the 
production of processed antigens to the T cells. Both 5-ASA and Sulfasalazine inhibit T cells and 
natural killer cytotoxic effective cells. They also impair addition, chemotaxis, block Interleukin-1 
production and of pro-inflammatory cytokines like Tumor Necrosis Factor. Both the compounds 
5-ASA and Sulfasalazine inhibit production of cyclooxygenase, prostaglandin, 5-lipoxygenase 
and 5-lipoxygenase activating protein. Both the agents inhibit the initiation of nuclear factor – KB 
(NF B) that plays an important role in activation and increased expression of genes for most of 
the pro-inflammatory cytokines, chemokines, addition molecules and inflammatory initiators. All 
of these are crucial perpetrators of development and progress of inflammatory bowel diseases 31. 
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The following picture is of the molecular structure of 5- ASA35 
 
 
 
 
 
 
 
1.8 INNOVATIVE THERAPEUTIC STRATEGIES FOR PREVENTION AND CONTROL OF 
THE DISEASE 
a) Rapidly Metabolizing Steroids: Corticosteroids are known for their long-term side effects 
and high toxicity, which is attributable to their pharmacology. Current research in 
pharmacokinetics and pharmacodynamics has greatly reduced the toxicity levels of the drug. 
Hence the current steroids have same clinical effectiveness for inflammatory activity 
without the side effects36.   
b) Bismuth Enema: Bismuth has shown great promise in reducing diarrhea, as it appears to 
bind tissue-damaging toxins in infectious stools37. 
c) Lidocaine Enema: Researchers believe Lidocaine reduces the hyperactive nerve reflexes, 
which are responsible for neuroimmune interactions. The inhibition causes subsequent 
inactivity of inflammatory cytokines38.  
  
Figure  4:  Molecular  Structure  of  5-­‐  Amino  Salicylic  Acid  
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d) RDP-58: The drug is the core part of this thesis report; the drug is studied in combination 
with a dissolving medium called Labrafil. RDP-58 is an anti-inflammatory decapeptide, 
which controls and inhibits TNF, IFN-Gamma, IL-2 and IL-12. It also inhibits an antibody 
directed to CD-3 cells39. 
e) Probiotics: These are live cultures of bacteria and microbiologic food agents that interact 
with the micro flora of the intestines. Several studies have shown that these agents can be 
used to reduce the severity of the symptoms but cannot treat the underlying cause. The 
studies also support the dogma that internal environment also plays an important role in the 
pathophysiology of the disease40. 
1.9 DEXTRAN SULFATE  SODIUM (DSS) MODEL OF ULCERATIVE COLITIS IN THE 
ANIMAL MODEL OF MICE 
Drug discovery often rely upon animal models that serve as surrogates of the human 
condition. Animal models help understand disease mechanisms and facilitate preclinical 
testing of diagnostic, preventive or therapeutic interventions. Animal models translate basic 
findings and help understand pathogenesis of diseases. Developing an animal model is an 
enduring process. Animal models can be developed by a) altering biologic pathways known 
or suspected to be involved in human diseases; b) by screening for phenotypes related to 
those associated with human diseases in spontaneous or induced mutant animals; c) by 
monitoring phenotypes in animal models that are induced through pharmacologic, dietary or 
environmental factors and recapitulating mutations associated with human genetic 
susceptibility loci. The animal model we employed in this is a chemically-induced model 
where animals when they drink 3-5% of DSS solution develop experimental colitis that is 
reminiscent of human ulcerative colitis. Animals develop an acute form of inflammation at 
the third day of the study when they are administered DSS once every day and they have a 
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full disease on the seventh day of the DSS cycle. The other form of disease is chronic 
inflammation; this is the more advanced stage of the disease. To create this form of the 
disease, the animals are fed 4% DSS for seven days and then they are given plain water for 
the next fourteen days, at the end of this cycle they are riveted back to 4% DSS for another 
seven days. This creates a chronic form of the disease50-53. The primary characteristics of 
acute inflammation are increased number of neutrophils in the mucosal layer, shortening of 
epithelial crypts, hyalination in the lamina propria and this is accompanied with severe 
weight loss, diarrhea and blood in the stool. Chronic inflammation is typified by a 
regenerating crypt layer and presence of a mixed concoction of macrophages, monocytes 
and lymphocytes in the mucosal layer. This form of disease gives an opportunity to study 
the efficacy of drugs and compounds due to its lengthy time period50. The most striking 
feature of this model is that it works using a very simple pathway to produce the disease as 
DSS overcomes the barrier of the epithelium to expose the mucosa to the flora present in the 
intestine resulting in an inflammatory response; this in turn leads to activation of 
macrophages and monocytes. The model also shows close links to the disease in human 
beings and also the fact that it is very simple to induce and reproduced weigh in its favor50, 
52, 54. 
1.10 DISEASE ACTIVITY INDEX 
Disease Activity Index (DAI) is a measure of the effectiveness of the disease induced by the DSS 
model. A scale of 0 to 4 is used to quantify the disease with 3 being the most advanced stage of 
the disease. DAI is scored on the parameters of weight loss, consistency of the stool and presence 
of blood in the stool. This index shows a linear correlation with the histology score based on 
changes in the architecture of the crypt 52.  
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1.11 PLASMA PROBE DESIGN AND FLOW SETUP 
Miniature Pin-to-hole Spark Discharge (M-PHSD) plasma generator is the set up which was 
designed and constructed at The Hess Plasma Laboratory of Drexel University, Philadelphia by 
Mr. Danil Dobrynin and Dr. Greg Fridman in conjunction with the current project. The M-PHSD 
system consists of a coaxial cathode and needle-like anode (Figure 5). The gas is fed through the 
capillary to the discharge gap. The anode is connected with the positive lead of the power source 
and the cathode is grounded. The discharge is a specific plasma sphere with the diameter ~2 - 3 
mm, atmospheric air is fed through the capillary at 0.2 – 0.5 atm, the discharge voltage is 0.5 - 1 
kV, the pulse duration is about 50 ms, the total power was kept on the order of 0.1 – 0.2 W57,58. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure  5:  A  schematic  of  plasma  probe  designed  for  the  study  by  Danil  Dobrynin  and  Gregory  
Fridman  
  
Metal tube (ground)
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Metal needle (positive)
Plastic tube
2 m
m
  
Figure  6:  The  plasma  probe  with  plasma  discharge  at  the  tip  
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Basic characteristics of the M-PHSD system: 
a. Plasma generating matter: atmospheric air 
b. Discharge voltage: 0.5 - 1 kV 
c. Plasma diameter: 2 – 3 mm 
d. Frequency: 1 – 7 Hz 
e. Average plasma gas temperature: 300 – 330 K 
The principal scheme of the power supply is presented on Figure 7. In order to produce pulses a 
capacitor is connected in parallel with electrodes. The typical size of the capacitor is 0.01 – 1 µF. 
When the breakdown occurs, a short pulse discharge will be formed between the two electrodes. 
The pulse duration is several micro seconds with a pulse frequency of typically 1-7 Hz.   
 
Figure 7: The principal scheme of the M-PHSD plasma power supply designed for the study by Danil Dobrynin 
and Gregory Fridman 
 
Plasma afterglow temperature at the exit nozzle was measured using thermocouple. The average 
temperature of the plasma afterglow is slightly above room temperature, and therefore it is 
completely safe to touch the plasma. 
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2. PROJECT RATIONALE 
Innumerable diseases have an inflammatory response among them the most common forms 
include inflammation caused by foreign substances, physical injury, autoimmune, infectious 
and ischemic origin. The progress of disease often leads to an inflammation which is 
significantly marked by infiltration of the site of injury with neutrophils and macrophages. 
Hence, this inflammation presents a very good opportunity to understand the dynamics and 
mechanics of complex and intricate diseases. The disease model is a well researched and 
highly used system to create colitis in mice. The platform that inflammatory bowel disorders 
provide is very firm as the gastro-intestinal disease market is very huge. In the U.S alone 
IBD cases have been responsible for over 152,000 hospitalizations each year. Over one 
million Americans suffer from one or other forms of IBD. The medical cost annually on IBD 
in United States alone is estimated to be over 4 billion USD. Hence, this provides a very 
interesting and challenging milieu to channelize the energies towards prevention or a cure. 
The pharmaceutical industry created a novel compound called RDP-58 as a controlling 
substance against ulcerative colitis, the project was to test the efficacy of this drug and of 
the formulation where this drug was encapsulated in Labrafil. The extensive experience and 
knowledge pool the laboratory had acquired over the years had provided a wonderful 
opportunity to test this drug in the DSS model of colitis in mice by the researchers in the 
lab. The next logical step in the march towards finding a way to control the disease was look 
into the physical aspect of manifestation of the disease. Cold Plasma technology provided a 
unique springboard to try and cure the disease using a mechanical and physical approach 
instead of internal drugs. The close correlation between the way plasma functions and 
behaves in contact with living tissue and the modus operandi of drugs focused against 
ulcerative colitis outweighed the odds and the project was green flagged to administer 
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plasma inside a living animal for the first time ever. The pivotal objectives of the whole 
project were:  
a. Understand the dynamics of ulcerative colitis in mice and to study the efficacy of a drug 
RDP-58 and a novel formulation of RDP-58 suspended in Labrafil. 
b. To integrate ‘state of the art’ cold plasma technology and medical biology and manifest 
it onto an ulcerative colitis platform.  
c. To study the interaction capability and juxtaposition of cold plasma technology with 5 
Amino Salicylic Acid; which is the standard of care for controlling ulcerative colitis.  
3. MATERIALS AND METHODS: 
3.1 STUDY DESIGN  
The study consisted of two broad divisions. These were divided into two protocols for the first 
division and into three protocols for the second division. A total of five whole experiments were 
conducted to understand the modus operandi in the development of DSS-induced experimental 
colitis in mice and to observe how certain therapies may provide therapeutic benefit in the mode. 
The following table explains in a bird view the whole study.  
 
 
 
 
 
 
22  
  
 
Experiment:  Primary Mode 
of Therapy 
Concentration 
and Time of 
Application 
Percentage of 
DSS (%) 
Total 
No. of 
Animals 
Purpose of Study 
1A.  Acute 
Study 
RDP-58 in 
Labrafil 
5 mg/kg per 
day 
2.5 32 
Efficacy of RDP-58 
in Labrafil 
1B.  Chronic 
Study 
RDP-58 in 
Labrafil 
5 mg/kg per 
day 
4 32 
Disease Reduction 
of RDP-58 in 
Labrafil 
2A. Plasma 
Pilot Feasibility 
Study 
CAP 
Treatment 
0, 4, 30 and 60 
seconds 
0 12 
To ascertain the 
toxicity levels in 
healthy animals due 
to application of 
plasma 
2B. Plasma 
Dose Response 
Study 
CAP 
Treatment 
0, 4, 30 and 60 
seconds 
2.5 24 
To decide which 
dosage of CAP is 
most effective in 
the model 
2C. Plasma as 
an Adjuvant to 
5-Amino 
Salicylic Acid 
CAP 
Treatment 
+ 5-ASA 
30 seconds, 80 
mg/kg per day 
2.5 24 
To check the 
effectiveness of 
CAP as an adjuvant 
to 5-ASA treatment 
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In all the experiments Female Swiss Webster mice approximately eight weeks old weighing 25 to 
30 grams were used. All these animals were housed in the vivarium in separate cages based on 
their groups in the animal facility at Drexel University College of Medicine. RDP-58 peptide for 
the whole experiment was provided in two different formulations (1) Lyophilized in a sachet (2) 
In a capsule.   
3.2 EVALUATION OF DISEASE PROGRESSION AND ACTIVITY OF CLINICAL COLITIS  
The most important and critical part of the whole study is the evaluation of disease prevalence in 
the animals induced with colitis. A proven and accepted measure of disease progression in this 
animal model is a holistic index of clinical parameters generally called Disease Activity Index 
(DAI). The DAI in animals is scored by a cumulative add-up of body weight, hemoccult 
reactivity, stool consistency and presence of visible blood in the stool 50, 52. The DAI is measured 
on a scale of 0-3 where 0 represents no clinical disease and 3 represents most severe disease. In 
the DSS model, it takes 7 or 8 days of the DAI to reach a score of 3.0.  In the parallel study, the 
DAI was allowed to reach 3.0 and the disease is representative of acute inflammation. In the 
chronic study, DSS is fed in two cycles.   The first cycle consisted of feeding DSS for 7 days, 
when mice reached DAI of 3.0, DSS was discontinued and mice were returned to drinking plain 
water for 14 days.  In the second cycle, animals were re-fed DSS for 7 days until they reached a 
DAI of 3.0 and the treatment was initiated and the treatment was continued for eight days.  
During the whole length of the study, animals were monitored everyday for changes in weight, 
stool consistency and appearance of occult (invisible) blood or gross bleeding.   
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3.3 DETAILED PROTOCOL FOLLOWED DURING THE SPAN OF THE COMPLETE STUDY 
3.3.1 ACUTE STUDY FOR RDP-58 IN LABRAFIL IN THE DSS INDUCED MOUSE COLITIS 
MODEL 
Goal of the Study: To study the efficacy of two formulations of RDP-58 dissolved in Labrafil and 
water respectively. DSS model of disease induction was used in the same. The study was 
conducted over a period of seven days.  
PROTOCOL:  
3.3.1.1 Study Initiation/Experiment Setup:  
a. Preparation of DSS: 25 grams of DSS (Batch # 6488B opened on 10th April 2008), was 
dissolved in 1 liter of water to make 2.5% DSS solution. This was stored at 8qC before use. 
b. Preparation of RDP-58 peptide in water: 1 sachet of the drug provided was dissolved in 80 ml 
of water and was stirred until the peptide completely dissolved. The concentration of RDP-58 
in the solution was 1.25 mg/ml; the whole procedure took up to two hours. The solution was 
aliquoted in microfuge tubes, and the tubes were stored at -20qC before use. The solution was 
thawed at 37° C for thirty minutes before use each day.  
c. Preparation of RDP-58 peptide in Labrafil: The capsule provided was coated with Labrafil 
and this capsule was dissolved in 80 ml water by stirring it for 4 hours. A white semi-solid 
mass (gunk) floated in the yellow turbid solution. This solution was removed from the 
mixture avoiding the gunk. The concentration of RDP-58 in this solution was 1.25 mg/ml. 
The solution was aliquoted into microfuge tubes and stored at -20qC before use. The solution 
was thawed at 37° C for thirty minutes before use each day.  
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d. Preparation of Labrafil (Control): 1 ml of Labrafil was dissolved in 79 ml water by stirring 
for 2.5 hours and this solution was aliquoted into microfuge tubes and stored at -20 qC before 
use. The solution was thawed at 37° C for thirty minutes before use each day. 
3.3.1.2 Animal Study: 
a. Four groups of animals were used for 4 different treatments. 
x Treatment 1 - RDP-58 in Water  
x Treatment 2 - RDP-58 in Labrafil 
x Treatment 3 -  Labrafil (Control)  
x Treatment 4 - Water (Control) 
b. Mice that arrived were acclimatized to vivarium conditions for two days before the study. 
c. Thirty two Mice were used in the study. They were divided into 8 cages with 4 animals per 
cage, 2 cages were randomly designated for each group.  
d.  On the first day all the animals were weighed and their individual Pre-DSS weight was 
ascertained. DAI was measured every day through the course of the experiment. 
e.  Mice were fed 2.5% DSS Solution in a feeding bottle for up to six days, they were treated in 
parallel with 0.1 ml of either oral water alone, Labrafil alone, RDP 58 dissolved in water or 
RDP 58 dissolved in Labrafil.  RDP 58 was used at a dose of 5mg/kg /day for six days and 
administered using a gavage needle.  
f. On the seventh day (after six days of therapy), the animals were euthanized with an overdose 
of Nembutal. Animals were exsanguinated (second kill). 
g.  Blood and colonic tissue samples were collected for histopathological and other biochemical 
analysis.  
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3.3.1.3 Euthanasia  
On the day of euthanasia, animals were euthanized with an I.P dose of 5 mg of Nembutal (0.1 
ml), the anesthesia was confirmed using the toe reflex by pinching the toe. The time given for 
them to reach an anesthetized state was ten minutes. A laparotomy was performed and the colon 
was exposed. A colon tissue was surgically removed and cleaned in saline and was jelly-rolled 
onto a wooden stick and stored in formalin. Blood was obtained from the heart and was stored for 
further analysis.  
3.3.2 CHRONIC STUDY FOR ASCERTAINING THE DISEASE REDUCTION POTENTIAL OF 
RDP-58 IN DSS INDUCED MODEL OF MOUSE COLITIS 
Purpose of the Study:  
To understand the disease control and reduction capability of two formulations of RDP-58 
peptide dissolved in Labrafil and water respectively.  
3.3.2.1 Study Initiation/Experiment Setup:  
a. Preparation of DSS: 40 grams of DSS was dissolved in 1 liter of water to make 4% DSS 
solution. This was stored at 8qC before use. 
b. Preparation of RDP-58 in water: 1 sachet of the drug provided was dissolved in 80 ml water 
and stirred for 2 hours. The solution was aliquoted in microfuge tubes, and the tubes were 
stored at -20qC before use. 
c. Preparation of RDP-58 in Labrafil: The capsule provided was coated with Labrafil   and this 
capsule was dissolved in 80 ml water by stirring it for 4 hours. The solution was aliquoted 
into microfuge tubes and stored at -20qC before use. 
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d. Preparation of Labrafil (Control): 1 ml of Labrafil was dissolved in 79 ml water by stirring 
for 2.5 hours and this solution was aliquoted into microfuge tubes and stored at -20 qC before 
use. 
3.3.2.2 Animal Study: 
a. Four groups of animals were used for four different treatments. 
x Treatment 1 - RDP-58 in Water  
x Treatment 2 - RDP-58 in Labrafil  (low-dose) 
x Treatment 3 -  RDP-58 in Labrafil (high-dose)  
x Treatment 4 -  Water (Control) 
b. Mice that arrived were acclimatized to vivarium conditions for two days before the study. 
c. Thirty two Mice were used in the study. They were divided into 8 cages with 4 animals per 
cage, 2 cages were designated for each group.  
d.  On the first day all the animals were weighed and their individual Pre-DSS weight was 
ascertained. DAI was measured every day through the course of the experiment.  
e.  Mice were fed 4% DSS Solution in a feeding bottle for seven days or until the animals 
reach a DAI of 2.6 – 3.0. DSS was stopped and the animals received plain water (no DSS) 
for 14 days. After the duration of 14 days, the animals were re-challenged with 4% DSS 
until they reached a DAI of 2.6-3.0.  
f. At the end of the cycle of 14 days the animals were administered with 0.1 ml of either oral 
water alone, RDP-58 dissolved in water, RDP-58 dissolved in Labrafil at a lower-dose and 
RDP-58 dissolved in Labrafil at a higher-dose.  RDP-58 was used at a dose of 5mg/kg/day 
for eight days administered using a gavage needle.   
28  
  
g. On the ninth day (after eight days of therapy), the animals were euthanized with an overdose 
of Nembutal. Animals were exsanguinated (second kill). 
h. Euthanasia was performed exactly as described in the afore mentioned protocol. The blood 
and colonic tissue samples were collected for histopathological and other biochemical 
analysis.  
3.3.3 THE SECOND STAGE OF THE STUDY CONSISTED OF UNDERSTANDING THE 
APPLICATION OF A TRANSLATIONAL THERAPEUTIC TREATMENT USING AN 
ADVANCED COLD PLASMA PLATFORM 
In this study CAP is used instead of a drug in the same model of DSS induced colitis in mice as a 
treatment and disease containing agent.  
PROTOCOL:  
3.3.3.1 Chronological Outline of the Study: Pilot Feasibility and Toxicity Study in Healthy 
Animals  
a. A total of 12 animals were housed at the vivarium and were acclimated for three days in 
animal house conditions.  
b. The animals were divided into four groups with three animals in each. (n = 3/ group) 
x 0 seconds of CAP treatment  
x 4 seconds of CAP treatment 
x 30 seconds of CAP treatment 
x 60 seconds of CAP treatment 
c. Animals were anesthetized with 0.4 ml I.P Nembutal, the effect of the anesthetic was checked 
using the toe relax by pinching.  
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d. A laparotomy was performed and the colon was exposed and kept moist using saline with a 
gavage needle.  
e. The CAP probe (2 mm O.D) was introduced through the anal verge up to 4 cm into the colon. 
Preselected dosage of plasma treatment was administered for 0, 4, 30 and 60 seconds in the 
respective group. CAP was introduced as a single discharge.  
f. The probe was removed and the mice were injected with I.V 30 mg/kg of Evans Blue (EB), 
ten minutes after the administration colon is washed with 1 ml physiological saline. The 
presence of EB in the colonic lavage was looked into using a Spectrophotometer. The 
absence of EB in the lavage showed that there was no damage to the mucosa due to CAP 
treatment.  
g. The colon tissue samples were surgically removed and were preserved for further 
histopathological analysis. The animals were euthanized with an over dose of Nembutal and 
were disposed off.  
3.3.3.2 Ascertaining the Ideal Dose of CAP response in DSS Induced Mouse Colitis Model 
a. Twenty four mice were housed in the vivarium and were acclimatized for three days.  
b. The mice were divided into four groups with six animals per group. The animals were placed 
in respective cages and were labeled accordingly (n = 6 / group).   
x Control ( 0 second CAP) 
x 4 second CAP 
x 30 second CAP 
x 60 second CAP 
c. All groups of mice were fed 2.5% DSS ad libitum for six days. Every alternate day starting 
with day 2 (days 2, 4, 6) animals were sedated with 5% isofluorane (tapered to 3 % after three 
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minutes per advise of University Veterinarian). The colon was cleansed with saline before 
inserting the probe.  
d. The CAP probe (2mm O.D) was introduced through the anal verge up to 4 cm into the colon.  
e. Gradually withdrawing the probe by 1cm four doses of CAP (0, 4, 30, 60 seconds) was 
administered starting at 4cm from the anal verge. Animals were allowed to recover for one 
whole day before introducing CAP again.  
f. Disease Activity Index was scored every day through the span of the experiment.  
g. After six days of DSS feeding and final CAP treatment on day 6, DAI was measured on day 7 
and the animals were surgically operated on to remove a tissue specimen of the colon after 
they were anesthetized with 0.04 ml of Nembutal.  
h. Animals were euthanized with an over dose of Nembutal and were exsanguinated. Colon 
tissue was preserved for further histological analysis.  
3.3.3.3 A Study of Effectiveness of CAP as an Adjuvant to 5-Amino Salicylic Acid (5-ASA) 
Treatment 
Based on the experiment above, 30 second CAP showed the best results in controlling and 
reducing the disease progression compared to all other groups. Hence, 30 second CAP was 
selected for the following experiment.  
a. Twenty four animals arrived at the vivarium and were acclimated for three days.  
b. Mice were divided into four groups with (n = 6 per group) 
x Control (No drug and 0 second CAP treatment) 
x 30 second CAP treatment  
x 5-ASA [2mg/ mouse /day 0.1 ml, oral gavage] 
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x 30 second CAP + 5-ASA (2mg/ mouse /day P.O 0.1 ml) 
c. All four groups of animals received 2.5 % DSS for six days. On days 2, 4 and 6 they 
received 2.5 % DSS dissolved in water and for days 1, 3 and 5 (one day before plasma 
treatment) they received 2.5% DSS dissolved in 15% Poly Ethylene Glycol based laxative to 
clean the colon and rid it of stool specks.  
d. One group at a time animals were sedated with 5% Isofluorane (tapered to 3% after three 
minutes per advice of University Veterinarian) on days 2, 4 and 6.  
e. CAP probe (2 mm O.D) was introduced into the colon 4 cm into the colon from anal verge 
in groups b and d, where group b received 30 second CAP treatment only while group d 
received 30 second CAP treatment in lieu with 5-ASA.  
f. 0.1 ml of 5-ASA was administered to groups c and d, where group c received 5-ASA only 
and group d received 5-ASA in combination with 30 second CAP.   
g. Animals were allowed to recover for one whole day and the DAI was scored everyday 
during the tenure of the study.  
h. On the seventh day after six days of DSS treatment and final CAP introduction DAI was 
measured and animals were euthanized with an over dose of Nembutal after the colon tissue 
was collected for further histological analysis 
  
32  
  
4. RESULTS AND DISCUSSION 
4.1 RDP-58 PARALLEL STUDY 
In this study four groups of animals were tested; each group had eight animals each making it a 
total of thirty-two animals in duration of one week. Furthermore, to understand the graphs 
illustrated below, each group is associated with a color code.  
 
Graph 1: Mean DAI: Progress of Colitis 
The current graph is a scatter plot of the four groups of animals. On the X-axis the days of 
observation are plotted and on the Y-axis the mean Disease Activity Index is plotted. This graph 
demonstrates that the disease has progressed in the water control group gradually over the period 
of seven days going from 0 on day 1 to 2.5 on day 7 (blue).  As this is the control group, the 
disease reduction in other groups will use this trend line as the base curve. The other control 
group of Labrafil (red) also shows a similar trend line of no disease reduction until day 3.  A 
slight decrease was observed in the DAI on day 4 and further decrease on day 5. A sudden spike 
was observed on day 6 and the DAI reached 2.0. This shows that the Labrafil control reduced the 
disease on two days, but it was not statistically significant. The drug group RDP-58 in Labrafil 
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(purple) illustrated comparative disease similar to both the control groups. The drug was being 
released in the Labrafil encapsulation and significant difference between controls and the drug 
groups was observed on days 2 and 3. But on day 6 on the day of severe disease, DAI spiked to 
2.0. The observation here is that the drug encapsulated in Labrafil is not effective on the day 
when the disease is at its peak. The disease in this group did not go above 1.0 on any day during 
the whole course of the study. The disease is controlled significantly on all the days with 
statistical significance observed on days 3, 4, 5 and 6 on comparison with the water (control) 
group. On day 6, there is a significant reduction in the disease in this current group as compared 
to all the other groups and the DAI is slightly shy of 1.0 where as all the other groups have a DAI 
of over 2.0. The final group of RDP-58 in water (green) is the best formulation for control of DSS 
induced colitis as shown by our study. The study proves that RDP-58 is very effective for the 
control of the disease during the induction phase of the disease and at the time when the disease 
was severe in control animals.  
 
Graph 2: Comparison of DAI: RDP-58 in Water vs. Water (control) 
The current graph is a Bar Exploration Graph; the two groups of RDP-58 in water (green) and 
water control (blue) have been compared on the parameters of days of observation and mean DAI 
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with days of observation on the X-axis and mean DAI on the Y-axis. It is observed that the 
disease gradually increases from 0.2 to 2.2 in the control group and the disease is controlled 
within 1.0 DAI in the drug group even on days of severe disease activity. There is a statistical 
difference in the disease levels between the groups on days 3, 4, 5, and 6. On the day of 
maximum disease RDP-58 in water controls the disease significantly as the drug group shows a 
disease activity index of 0.9 whereas the control group stands at 2.2. This study shows clearly that 
the drug is effective in controlling the disease as compared to the control.  
 
  Graph 3: Comparison of DAI: RDP-58 in Labrafil vs. Labrafil (control) 
The current figure is a Bar graph exploring the dynamics of RDP-58 in Labrafil (purple)  and the 
control group receiving Labrafil (red)  alone. The graph shows a steady progression in the DAI 
from day 1 to day 6 in the Labrafil control group with a slight abnormality on day 4 where the 
disease dips a slight bit. The disease goes from 0.2 to 2.1 on the DAI scale in the control group. It 
is observed that there is not statistical difference on any of the days in the groups. The group of 
RDP-58 in Labrafil also shows a steady increase in DAI through the course of the study with it 
reaching a peak on day 6 and on this day there is no difference between the control group and the 
35  
  
drug induced group. This fortifies the claim that RDP-58 is a good drug when dissolved in water 
but is not as effective when encapsulated in Labrafil.  
 
Graph 4: Comparison of DAI: RDP-58 in water vs. RDP-58 in Labrafil 
The current graph explores the relation between the drugged groups, one in water (green) and the 
other in Labrafil (purple). Days of observation are on the X-axis and mean DAI on the Y-axis. 
The disease shows a steady growth from day 0 to day 6 in the RDP-58 in Labrafil group. The 
disease reaches a high of 2.2 on day 6 which is exactly what was observed in the control groups. 
However, the RDP-58 in Water group shows a significant reduction of the disease on all the days 
and as a significant statistical difference on days 4 and 6. The disease never crosses 1.0 on the 
DAI scale through the course of the study. Even during the day of maximum disease the RDP-58 
in Water group curtails the DAI to 1.0. This illustrates that RDP-58 in water is a good 
formulation as compared to that of encapsulated in Labrafil. 
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Graph 5: Length of the Colon in the four groups 
 
The present graph represents the length of the colon in each group, on the day of sacrifice.  The 
data is an average of all the animals belonging to each group. It is clear that lengthier the colon, 
healthier the animal. The length is plotted on the X-axis and the four groups are plotted on the Y-
axis. We observe that the water control group has the shortest colon in the set, which implies that 
these are the sickest animals. The control group of Labrafil (red) also have short colons just 0.1 
cm longer than that of the Water (control) (blue) group. The RDP-58 in Labrafil (green) group 
has an average colon length of 6.6 cm and the most effective drug therapy group of RDP-58 in 
water (purple) has the longest colon length of 6.9 cm showing that this group is the healthiest 
animal set. Hence we corroborate evidence using physical observation of surgically removed 
colon length to prove all that is observed in the above battery of tests. RDP-58 in water is the best 
group in terms of disease control and reduction.   
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Graph 6: Total Inflammation Scores: RDP 58 Parallel Study 
The present graph is a representation of the total inflammation of the colon in the different groups 
based on histological analysis of the tissue specimen. It is observed that the control group has the 
maximum inflammation of 8.1 on the inflammation score and the drug group of RDP 58 in Water 
has the minimum inflammation of 3.8 compared to all the groups. The graph verifies that the data 
acquired by histological analysis is in direct relevance to that acquired by the procedure 
conducted in the laboratory.  
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Graph 7: Chronic Inflammation Scores: RDP 58 Parallel Study 
The current graph is a representation of chronic inflammation of the colon in the different groups 
based on histological analysis of the tissue specimen. It is inferred from the data that the control 
group has the highest prevalence of chronic inflammation as compared to any other group. The 
drug group of RDP 58 in Water has the minimum chronic inflammation of 1.8 compared to all the 
groups. The graph corroborates that the data acquired by histological analysis is in direct 
relevance to the DAI scored in the laboratory.  
4.2 RDP-58 CHRONIC STUDY  
This is the second stage of the RDP-58 study. In the study a total of 32 animals were used. They 
were divided into four groups with 8 animals each. The study was conducted over a span of 33 
days. In the first step, the disease was induced into the animals for seven days until they reached a 
DAI of 2.9. In the second step the animals were given plain water in place of DSS and the disease 
was allowed to reduce naturally by the host’s immune system for 14 days. In the third step the 
animals were re-challenged with DSS and the disease was allowed to go up to 3.0 on the DAI 
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scale for 7 days. In the final step, animals were given plain water without DSS and were 
administered with different doses of the drug and one group was observed as a control and it did 
not receive any drug. The four groups were Water (control) (blue), RDP-58 in Water (red), RDP-
58 in Labrafil (low dose) (green) and RDP-58 in Labrafil (high dose) (purple).  
 
Graph 8: Progress of Therapy 
The current figure is a scatter plot of the eight days of treatment. This is the last stage of the 33 
day study. At the onset of this phase, DAI is at a high of 3.0 on day 26 and the animals are at a 
stage of chronic form of the disease. All four groups were allowed to recover and the three drug 
groups were administered RDP-58 in varied doses and using different vehicles. On the X-axis the 
Days of the Therapy are plotted and on the Y-axis Mean DAI is plotted. The Water (control) 
group shows a decline in DAI level in a regressive trend. This shows that the immune system is 
working to reduce the disease and the lowest the control group goes on the DAI scale is 1.4. The 
drug group of RDP-58 in Labrafil at a lower dose takes the disease steadily lower to 0.9 on day 8 
when the disease is at the lowest. The other drug group of RDP-58 in Labrafil at a higher dose 
works better than the lower dose administration as it reduces the disease further at a faster slope 
and takes DAI on day 8 to 0.5. As observed in the previous stage of the study RDP-58 in water 
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works well even in the chronic form of the disease and facilitates rapid recovery during the 8 days 
of treatment.  The disease decreases rapidly in this group of animals as DAI drops drastically 
right from day 26 and reaches a near 0 on the DAI scale. This group of animals is in good health 
compared to any other group of animals and no weight loss is observed.  
 
Graph 9: Progress of Colitis 
Note: The Standard Error is not represented in the graph as the graph would be cluttered owing 
to the number of data points. 
The scatter plot of the Progress of Colitis observed during the span of 32 days is shown in the 
following figure. Four groups of animals were fed 4% DSS until their individual DAI reached 
3.0. Animals were fed plain water for the next 14 days and the DAI was brought down to near 0. 
The animals were re-challenged with DSS and the DAI was taken again to 3.0. It took 7 days for 
the re-induction of the disease. The animals were reverted to plain water and were treated with 
the drug RDP-58 in three groups and one group was not administered any drug. The graph shows 
the cycle of induction, disease reduction, re-induction and treatment. In the re-induction phase of 
the study, the animals were more susceptible to the disease as the system was already 
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compromised due to the first invasion of the disease. Hence, the slope is steeper in the re-
induction phase. The last phase shows the treatment and recovery of the animal groups.  
 
Graph 10: DAI Comparison Water (Control) vs. RDP-58 in Water 
The following figure is a bar graph comparing the control group and the group with RDP-58 
dissolved in water. This is the best group showing maximum reduction in the disease through the 
course of 8 days of treatment. On day 1 of therapy, both the groups have a DAI of near 3.0. The 
disease steadily reduces in both the groups. However, the drug group shows a reduction in the 
disease with the disease reaching a near 0 on the DAI scale on day 8 in comparison with the 
control group having a DAI of 1.4 on the same day. This clearly elucidates the disease reduction 
of the drug and a statistical significance of DAI variation is observed on days 4, 5, 6, 7, and 8. 
This is due to the fact that the immune system and the drug combined work in conjunction in 
reducing the disease and controlling the damage caused by previous exposure.  
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Graph 11: RDP-58 in Labrafil (Low dose) vs. RDP-58 in Labrafil (High dose) 
The bar graph comparing two levels of drug administration is shown in the figure. On the day 1 
of therapy both the groups are at the DAI of 2.7. Both the groups show a decrease in the disease 
activity levels. However, a statistical significance is not observed in both the groups. The drug 
administered in a higher dose does reduce the disease a little more than that at a lower dose and 
the DAI on day 8 of therapy reaches 0.4 in the higher dose and is at 0.8 in the lower dosage of the 
drug. This observation further shows that the evidence gathered in the earlier experiment of RDP-
58 is not being released in Labrafil encapsulation and administering it at a higher dose is not that 
effective as compared to the drug administered in water as a vehicle.  
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Graph 12: Length of the Colon 
The length of the surgically removed colon was measured in each group on the day of the 
sacrifice. The length of the colon is plotted on the X-axis and the four groups are represented on 
the Y-axis. The healthiest of the four groups will have the lengthiest colon as the colon is not 
immune compromised and is not destroyed significantly by the disease. The control group shows 
the shortest average of colon length with RDP-58 in Labrafil (Low dose) showing a longer colon 
length. RDP-58 in water shows the longest colon reiterating the fact that the drug administered in 
water is the optimum group.  
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Graph 13: Total Inflammation Scores: RDP 58 Chronic Study 
The present graph is a representation of the total inflammation of the colon in the different groups 
based on histological analysis of the tissue specimen. It is observed that the control group in the 
chronic study has the maximum inflammation of 12.0 on the inflammation score and the drug 
group of RDP 58 in Water has the minimum inflammation of 7.6 compared to all the groups. The 
graph corroborates the data acquired by histological analysis is in direct relevance to that acquired 
by the procedure conducted in the laboratory.  
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Graph 14: Chronic Inflammation Scores: RDP 58 Chronic Study 
The current graph is a representation of the chronic inflammation of the colon in the different 
groups based on histological analysis of the tissue specimen. It is observed that the control group 
in the chronic study has the an inflammation of 5.9 on the inflammation score and the drug group 
of RDP 58 in Water has the minimum inflammation of 4.2 compared to all the groups. The graph 
demonstrates that the data acquired by histological analysis is in direct relevance to that acquired 
by the DAI scored in the laboratory.  
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4.3 PLASMA DAMAGE ASSERTION STUDY 
This is the first stage of the plasma phase of the study. The primary objective of the study was to 
ascertain if Cold Plasma administered in vivo in mice would cause any damage to the cells, tissue 
or the animal itself.  Twelve animals were anesthetized and four doses (0, 4, 30, and 60) of 
plasma was discharged, in three animals per group. Tissue damage was ascertained by Evans 
Blue (EB) extravasation and histology. Spectrophotometer of the saline fluid collected from the 
colon showed no trace of EB, showing that plasma did not affect the tissue architecture or 
constitution and it was histologically confirmed. This is due to the fact that the temperature of 
Cold Plasma is just slightly over room temperature. This does not cause any damage what so ever 
to the tissue, colon or the animal.  
 
 
Figure 8: Histopathology Schematic of the 0 Second (Control) Group Animal. 
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Figure 9: Histopathology Schematic of the 4 Second Group Animal. 
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Figure 10: Histopathology Schematic of the 30 Second Group Animal. 
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Figure 11: Histopathology Schematic of the 60 Second Group Animal. 
4.4 PLASMA EFFICIENCY PILOT STUDY   
The study is the second stage of the plasma project, after it was observed that plasma does not 
damage the tissue. The next step was to check the most efficient dosage of plasma, hence 12 
animals were divided into 4 groups each receiving 0,4,30 and 60 seconds (blue, red, green, purple 
respectively) of Cold Plasma every alternate day for 7 days. All the animals were fed 2.5% DSS 
for 7 days in parallel with plasma treatment. DAI was scored everyday to see which dosage of 
plasma was most effective in controlling the spread of the disease. For the plasma probe to be 
inserted and to go through the colon, the colon has to be cleansed of stool specks. To do so, the 
animals were fed a polyethylene glycol based laxative along with DSS on days before plasma 
treatment. However, the stool consistency on the next day was compromised as the laxative made 
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the stool consistently loose. Hence, the data extracted from the study was bifurcated and was 
analyzed using a three pronged approach considering: 
a. Weight, stool consistency and presence of blood in the stool. 
b. Weight and presence of blood in the stool (without stool data) 
c. Mean Hemoccult (visible blood in the stool)  
Twelve animals divided into four groups of control (no plasma), 4 second, 30 second and 60 
second.  
Note: The following graphs consider weight, stool consistency and presence of blood in the stool. 
 
Graph 15: Mean DAI: Progress of Colitis (Considering Weight, stool consistency and 
presence of blood in the stool) 
The scatter plot illustrates the DAI graphed against the days of observation of the animals during 
the 7 days of the study. The animals were fed 2.5% DSS ad libitum, for 7 days and four doses of 
plasma were administered every alternate day. The data shows that, in the control group the DAI 
scored using weight, stool consistency and blood visibility in the stool reaches a value of 2.3 by 
the end of 7 days. It grows gradually from 0 on day 1 and consistently goes up to 2.3 on the DAI 
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scale. As this group did not receive any drug or plasma treatment, the trend line will be used as a 
reference mark for the other groups. The group which received 60 second plasma reached a DAI 
of 1.6 on day 7. Hence, the disease is not controlled well in the 60 second plasma group; on days 
3, 4 and 5 60 second pulse stabilized the disease and prevented it from growing. However, as the 
severity of the disease increased the pulse dosage ceased to work effectively. This could be due 
to the assumption that over exposure of plasma might not be very useful in controlling the 
disease. 4 second plasma pulse shows disease reduction capability during the end stage of the 
study and it is comparatively better than the 60 second pulse. It shows good disease control 
through the course of the study. The most efficient dosage of plasma as shown by the study is 
that of the 30 second pulse. This group shows high resilience against the progression of the 
disease and as compared to the control, shows ability in stopping the growth of the disease even 
when DSS is being fed in parallel. The maximum DAI in this group is 1.2 as observed on day 7, 
the day of maximum disease prevalence. We can infer that this is the optimum dose of plasma, 
which can be used to effectively control the disease.   
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Graph 16: Comparison of DAI: Control vs. 30 Second Pulse (Weight, stool consistency and 
presence of blood in the stool) 
 
The data is represented in the form of a bar graph with mean DAI on the Y-axis and the days of 
observation on the X-axis. The two groups of control which received no plasma treatment what 
so ever and the 30 second plasma exposure group are represented in form of disease progression. 
It can be inferred from the graph that there is a difference between the disease activities in the 
two groups. The plasma group curtails the disease and does not allow the DAI to go over 1.2 
even on the day of maximum disease prevalence, on a contrast to the control group the disease 
activity reaches over 2.2 on the day 7 when maximum disease is observed. The 30 second plasma 
exposure group shows the most effective plasma treatment compared to the control, 4 sec and 60 
sec dosage. The data makes it clear that the plasma discharge of 30 second is reliable and 
effective in controlling the spread of colitis.  
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Note: The following graphs consider weight, and presence of blood in the stool (without stool 
data) 
 
Graph 17: Mean DAI: Progress of Colitis (considering weight and hemoccult only) 
The chart is a scatter plot with an added trend line to show the trend of the disease progression. 
The data is represented with mean DAI on the Y-axis and days of observation on the X-axis. 
Four groups of animals have been considered here and it is observed as a tweak on the earlier 
graph as only the changes in weight and hemoccult have been considered while generating the 
graph as the laxative that was administered to the animals on days prior to plasma treatment 
might have compromised the score based on stool consistency as this makes the stool 
comparatively loose. The graph shows clearly the extent to which the 30 second plasma group 
controls the DAI compared to the other groups of the study. The DAI on the new scale reaches a 
high of 1.5 on the control group but is at a range of near 0.5 on the 30 second plasma exposure 
group. The vantage point shows the statistical difference between the four groups as the absence 
of stool data also confirms the fact that 30 second plasma exposure group worked better 
compared to the control in the current study.  
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Graph 18: Comparison of DAI: Control vs. 30-second Pulse (considering weight and 
hemoccult only) 
The bar graph represents the data of comparison between the control and 30 second plasma pulse 
group with mean DAI on the Y-axis and the days of observation on the X-axis for a span of seven 
days. The 30 second plasma group clearly has a low prevalence of DAI even on days when the 
disease is projected to be sizable as it stops the DAI from going over 0.5 even on the ultimate and 
penultimate days. On comparison, the DAI in the control group reach a high of 1.5 on the final 
day of the study. This further shows that there is a statistically significant difference between the 
two extremes of groups.  
Note: The following graphs consider Mean Hemoccult (visible blood in the stool)  
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Graph 19: Mean Hemoccult: Progress of Colitis 
The scatter plot with a trend line is shown in the graph, the X-axis has the days of observation 
and the Y-axis has the mean hemoccult. In the set of data only the presence of visible blood in 
the stools has been considered as the primary responsibility of plasma is to coagulate the blood 
inside the inflamed colon. As the prime facet of tissue degradation of colitis is through bleeding 
out of the tissue which can be observed on the stool study. Hence, this data is critical to check if 
plasma can actually clot and coagulate the blood inside the colon. The data shows that there is a 
statistical significance between the control group and the 30 second plasma group, as the visible 
blood in the stool index shows that on the final days of study hemoccult reaches a high of 4 in the 
control group vis-á-vis the 30 second group has a DAI of just over 0.5. It can be inferred from the 
data that the 30-second plasma group is showing blood coagulation inside the colon along with 
the 4 second plasma group with 30 second group being a lot more effective on the final day of the 
study.  
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 Graph 20: Comparison of Hemoccult: Control vs. 30 Second Pulse 
The bar graph shows the mean hemoccult on the Y-axis and the days of observation on the X-
axis. The groups show a statistically significant difference in the presence of blood in the stool 
samples. Days 6 and 7 observes a difference between the two bars with mean hemoccult reaching 
4.0 in the control group when the hemoccult is at 0.6 on all days 4, 5, 6 and 7 in the 30 second 
group.  
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4.5 PLASMA AS AN ADJUVANT TO 5-ASA IN CONTROLLING COLITIS STUDY 
Note: The following graphs consider weight, stool consistency and presence of blood in the stool. 
 
Graph 21: Progress of Colitis: Mean DAI 
The chart shows the scatter plot of the data mined for the final leg of the study, the graph has the 
progress of colitis expressed with mean DAI on the Y-axis and days of observation on the X-axis. 
All the four groups show a linear increase in the disease as the days progress. However, the onus 
is on understanding the cumulative effect of the drug combined with plasma and its therapeutic 
stamp. There is a clear demarcation between the four groups of study. The control group as 
always shows a steady increase through the course of seven days with the DAI reaching an 
expected 2.7 on day 7. The plasma treatment group was administered 30-second plasma pulse 
and the data is in direct correlation with the data acquired in the previous study and it also shows 
a constant increase. However, the disease is curtailed to near 1.8 on the DAI scale. 5-ASA 
treatment group received the drug only without the plasma pulsing; as this drug is an industry 
standard in curing the disease, the spread of colitis is controlled and has a statistical significance 
over the control on days 5, 6 and 7. The objective of the study was to bring the advanced plasma 
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technology and the medical drug and see the interaction in the colitis model. The final group was 
designed and was administered the drug 5-ASA along with the plasma pulsing on every alternate 
day. The group showed very positive results as both in combination proved to be effective in 
controlling the disease and keeping the DAI on a level of 1.2 on the DAI scale. This is a sizable 
variation as compared to the control group and there is a difference of one whole point between 
both of them with a statistical significance observed on days 4, 5 6 and 7. 
 
Graph 22: Comparison of DAI: Plasma treatment vs. 5-ASA treatment vs. 5-ASA + Plasma 
treatment 
The graph is an extension over the earlier chart and this shows the variation in the DAI levels of 
the three doses of treatment. Plasma treatment alone shows certain disease control capability and 
the combination treatment shows good results on the final day even when the disease is at its 
peak.  
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 Graph 23: Comparison of DAI: Control vs. 5-ASA + Plasma treatment 
The graph clearly shows the variation in the control and the treated group as this is a statistically 
significant variation, it is inferred that the treatment has been effective in keeping the rampage of 
the disease at bay. This could be due to the fact that plasma takes care of the sterilization and 
coagulation of the blood in the colon and 5-ASA controls the disease by its tinkering of the 
biological pathway which mediates the progress of the disease.  
Note: The following graphs consider weight and presence of blood in the stool only (stool 
consistency is not considered) 
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Graph 24: Comparison of DAI: Control vs.  Plasma treatment vs. 5-ASA treatment vs. 5-
ASA + Plasma treatment 
The bar graph shows the DAI values of the four groups under consideration and is plotted against 
mean DAI on the Y-axis and the days of observation on the X-axis. The four groups show a 
variation on days 4, 5, 6 and 7. It was observed that the groups receiving the treatment of plasma, 
drug and their combination show a disease reduction, even when the stool consistency is not 
considered. This further elucidates that plasma has an application in coagulating the blood in the 
inflamed colon and that the disease can be controlled with direct contact with the area affected 
without tinkering with the biological pathways.  
 
 
 
 
 
 
61  
  
 
Note: The following graphs consider presence of blood in the stool only.  
 
Graph 25: Progress of colitis: Mean hemoccult 
The scatter plot is designed to express the mean hemoccult charted on a scale of 0 to 4 with 4 
being the advanced stage of the disease. The mean hemoccult is plotted on the Y-axis and the 
days of observation are plotted on the X-axis.  The objective of this line of analyzing the data is 
to check the hypothesis that plasma treatment has an effect on the blood observed in the stool. 
The mean hemoccult only shows the presence of blood in the stool and does not consider any 
other parameter. The plasma treatment shows a significant drop in the hemoccult scale as 
compared to the control which shows that plasma actually is working in clotting the blood that is 
being pumped out of the inflammed region in the colon. The combination treatment further 
reduces the hemoccult score as a two pronged approach is taken against the disease.  
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Graph 26: Comparison of Hemoccult: Control vs. 5-ASA drug treatment. 
The bar graph shows the mean hemoccult score on the Y-axis and the days of observation on the 
X-axis. The data demonstrates that the drug is effective in controlling the bleeding from the colon 
as this drug regulates the bio-pathways responsible for the inflammation. A disease reduction by 
the drug has a direct relevance to the amount of blood oozing out of the colon as the drug is 
tested already to be effective in controlling the disease. It is observed that its mechanism is by 
regulating the system into clotting the blood from the inside and by curing the inflamed tissue. 
The data shows that the drug alone has an impact in controlling the disease, what has to be 
observed is how plasma in combination with the drug fares.  
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Graph 27: Comparison of Hemoccult: Control vs. 5-ASA + Plasma treatment. 
 
The most important aspect of the study is to verify the hypothesis that plasma can be used as an 
adjuvant to the conventional drug treatment to cure the disease faster. The data shows that the 
group which received the combination treatment further pushed the disease down as compared to 
the groups which received the drug or plasma as stand alone. The bars show a statistical 
significance in the two groups as plasma and 5-ASA reduce the disease as compared to the 
control group on days 5 and 7.  
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5. CONCLUSIONS 
x In the first set of experiments of RDP-58, it can be inferred that RDP-58 dissolved in water 
is an excellent drug to control the progression of the disease in the acute stages of the 
disease.  However, RDP-58 encapsulated in Labrafil, RDP-58 dissolved in water worked 
better as shown by the data mined from the experiments.  
x In the second set of experiments, when RDP-58 was tested in the chronic form of the 
disease, RDP-58 again proved to be a better formulation when dissolved in water compared 
to drug encapsulated in Labrafil.  
x In the first stage of the plasma study, the primary goal was to understand the interaction of 
cold plasma with a living animal. The study showed that the cold plasma alone in graded 
doses did not cause any damage to the tissue or the animal based on Evan’s Blue 
extravasation and histology.  The study showed for the first time that plasma in graded doses 
can be used safely in vivo without any collateral damage.  
x The second stage of the study explored whether cold plasma would worsen the disease in an 
established animal model of experimental colitis.  The results of the study showed that 
plasma did not adversely affect the animals by worsening the disease.  Indeed, surprisingly, 
it reduced the disease level and the result was truly unexpected. Among various doses of 
plasma tested, 30 second dose of cold plasma showed most significant disease reduction 
based on the DAI scored.  
x The unexpected observation in the second stage of the study lead to us to compare whether 
cold plasma is an effective inhibitor of disease compared to standard of care therapy with 5-
ASA. Cold Plasma administered to the animals in graded doses reduced the disease in the 
animals compared to the control. 5- ASA group showed a better disease control compared to 
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the groups in which plasma alone was administered. However, the groups which received 
the combined therapy of 5 - ASA and 30 second Plasma discharge showed a statistically 
significant difference in disease control compared to the groups receiving the drug or plasma 
treatment alone.  
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6.  PATH FORWARD  
x The physical contact of plasma at the site of inflammation can be used to understand the 
mechanisms of how plasma may be therapeutic on a cellular and tissue level.  
x Since CP did not cause any adverse effects in healthy and unhealthy animals, the findings 
of the study have created an opportunity for the potential application of cold plasma in 
vivo. 
x The development of the probe presented with its own challenges as the animal model in 
consideration was pertaining to a small animal like mice. Hence, this technology will prove 
to be much more effective in larger animals as the probe can be made much bigger and the 
surface in contact with plasma will be much higher.  
x The stage can be set where this technology and disease model can be taken on to a 
translational medicine interface.  
x The study showed that this line of thought can have a significant advantage in the 
commercial arena of drug development as CP may reduce the costs and the care of the 
patient at the hospitals due to its simplicity and ease of application particularly in subjects 
with colonic inflammation and infection.  
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